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Abstract
CD34 selection significantly improves GVHD-free survival in allogeneic hematopoietic cell 
transplantation (allo-HSCT). Specific information regarding long-term prognosis and risk factors 
for late mortality after CD34-selected allo-HSCT is lacking, however. We conducted a single-
center landmark analysis in 276 patients alive without relapse 1 year after CD34-selected allo-
HSCT for AML (n=164), ALL (n=33), or MDS (n=79). At 5 years' follow-up after the 1-year 
landmark (range 0.03-13 years), estimated RFS was 73% and OS 76%. The 5-year cumulative 
incidence of relapse and NRM were 11% and 16%, respectively. In multivariate analysis, HCT-CI 
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score ≥ 3 correlated with marginally worse RFS (HR 1.78, 95% CI 0.97-3.28, p=0.06) and 
significantly worse OS (HR 2.53, 95% CI 1.26-5.08, p=0.004). Despite only 24% of patients with 
acute GVHD within 1 year, this also significantly correlated with worse RFS and OS, with 
increasing grades of acute GVHD associating with increasingly poorer survival on multivariate 
analysis (p<0.0001). Of 63 deaths after the landmark, GVHD accounted for 27% of deaths and 
was the most common cause of late mortality, followed by relapse and infection. While prognosis 
is excellent for patients alive without relapse 1 year after CD34-selected allo-HSCT, risks of late 
relapse and NRM persist, particularly due to GVHD.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established therapy for 
hematologic malignancies, including relapsed/refractory or high-risk acute myeloid 
leukemia (AML) or acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome 
(MDS). Yet transplant recipients remain at risk for relapse, and for late complications and 
non-relapse mortality (NRM). In particular, graft-versus-host disease (GVHD) is a 
potentially devastating complication. The use of T-cell depletion (TCD) of allografts by 
CD34+ cell selection has improved GVHD-free survival in acute leukemia and MDS without 
need for post-transplant immunosuppression and without increased risk of relapse.1-10
Previous analyses of multicenter data reported to the Center for International Blood and 
Marrow Transplant Research (CIBMTR) to evaluate prognosis for recipients of 
myeloablative allo-HSCT who survive without relapse past the early post-transplant period 
have found that long-term survival for these patients is excellent.11, 12 Possible risk factors 
for late mortality include chronic GVHD, relapsed/refractory disease, and poor performance 
status. These registry studies included patients who received both T-cell replete and TCD 
allografts, which in many cases employed older methods of TCD. Prognostic information is 
lacking for patients who undergo TCD transplantation using contemporary techniques and 
survive without relapse past the early post-HSCT period. This study therefore focused on 




The study included adult recipients of first allo-HSCT with a CD34+ cell–selected peripheral 
blood stem cell transplant (PBSCT) at Memorial Sloan Kettering Cancer Center for AML, 
MDS, or ALL between February 2000 and June 2013. All patients and donors provided 
written informed consent for treatment. The MSKCC Institutional Review and Privacy 
Board approved this retrospective study. High-resolution DNA-specific oligonucleotide 
typing characterized HLA-A, -B, -C, -DRB1, and -DQB1 loci. Clinical outcomes, including 
acute and chronic GVHD, relapse, and causes of death, were captured in real time per 
standard clinical practice.
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All patients received myeloablative conditioning. TBI-based regimens included the 
following: TBI 1,375 cGy in 11 fractions over 4 days, followed by thiotepa 5 mg/kg/day for 
2 days with either (1) fludarabine 25 mg/m2/day for 5 days beginning on the first day of 
thiotepa or (2) cyclophosphamide 60 mg/kg/day for 2 days starting after thiotepa.2, 3 
Chemotherapy-based preparative regimens consisted of intravenous busulfan 0.8 mg/kg/dose 
every 6 hours for 10 or 12 doses, melphalan 70 mg/m2/day for 2 doses, and fludarabine 25 
mg/m2/day for 5 doses; or clofarabine 20 mg/m2/day for 5 days, melphalan 70 mg/m2/day 
for 2 days, and thiotepa 5 mg/kg/day for 2 days (or 10 mg/kg for 1 day), each regimen 
specified by institutional protocol 10-050 (NCT01119066).6
CD34+ cell selection of PBSCs was accomplished by positive selection of CD34+ stem cells 
using the ISOLEX 300i Magnetic Cell Separator (Baxter, Deerfield, IL) followed by sheep 
RBC (sRBC) rosette depletion or, beginning in 2006 and exclusively after May 2010, using 
the CliniMACS CD34 Reagent System (Miltenyi Biotech, Gladbach, Germany) without 
need for additional sRBC rosette depletion of residual T-cells. Allografts were infused 
within 24–48 hours of completion of cytoreduction. Patients received no pharmacologic 
GVHD prophylaxis. Graft rejection prophylaxis consisted of antithymocyte globulin (Table 
1). Patients received supportive care and opportunistic infection prophylaxis according to 
institutional guidelines.
Study definitions and statistical analysis
GVHD was diagnosed clinically and confirmed histologically where appropriate. Acute and 
chronic GVHD were evaluated using International Bone Marrow Transplant Registry13 and 
National Institutes of Health consensus criteria,14 respectively. Cause of death was 
determined using the algorithm devised by Copelan et al., which employs a hierarchy of 
events to identify the underlying cause of death: For instance, if a patient dies of GvHD after 
donor lymphocyte infusion for relapse, relapse is the primary cause of death; if a patient dies 
of infection while on treatment for GvHD, GvHD is the cause of death.15 Disease risk and 
relapse were categorized using standard guidelines.16-18 In AML, as evaluation of molecular 
features including FLT3, NPM1, CEBPA, and c-kit mutational analysis became standard 
practice only during the course of the period studied, patients were stratified by cytogenetic 
features with incorporation of molecular data where available.
Kaplan-Meier methods estimated overall survival (OS) and relapse-free survival (RFS). 
Relapse and non-relapse mortality (NRM) were estimated with cumulative incidence 
functions. Given small numbers of patients with GVHD onset after the landmark, incidence 
of GVHD was characterized descriptively. All patients including those who underwent 
second allo-HSCT were included in accounts of GVHD. Association of characteristics with 
RFS and OS was evaluated using Cox regression. Variables significant to p≤0.05 were 
evaluated for association in a multivariable Cox regression model. Association between 
donor type and GVHD by 1 year was assessed using the Chi-square test. Competing risks 
analysis was performed using R version 3.2.4 (www.R-project.org). All other statistical 
analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).
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A total of 416 patients underwent CD34-selected allogeneic PBSCT for AML, MDS, or 
ALL. Of these, 276 patients were alive without relapse at the designated 1-year landmark 
and were included in the analysis. Of those excluded, 114 had died before 1 year; the 
remaining 26 were alive with relapse at 1 year. Table 1 summarizes patient and transplant 
characteristics. Median CD34+ cell dose was 7.6 × 106 cells/kg (range 0.6–31.2 × 106), and 
median CD3+ T-cell dose was 1.9 × 103 cells/kg (range 0–63.0 × 103). Twenty-one patients 
(8%) received donor lymphocyte infusion (DLI) before the 1-year landmark, in 17 cases 
(81%) for mixed chimerism without relapse, in 2 cases for minimal residual disease, and in 2 
cases to promote immune reconstitution in the setting of severe viral infection (JC virus and 
HHV-6). Nine patients in the landmark cohort (3%) had received a CD34-selected cell boost 
for poor graft function or secondary graft failure.
Table 1 summarizes disease-specific characteristics. In AML, 71% of patients were 
transplanted in CR1. The majority of patients had poor- (n=51, 31%) or intermediate-risk 
(n=95, 58%) disease. Mutations were present in 19/62 patients (31%) analyzed for FLT3 
(internal tandem duplication or tyrosine kinase domain variant), 4/46 (9%) for isolated 
NPM1 mutations, and 0/22 for CEBPA mutations. Thirteen (8%) had c-kit mutation testing; 
one of these (8%) was positive, in conjunction with inversion of chromosome 16. Eighty-two 
percent of patients with MDS underwent allo-HSCT with morphologic evidence of disease, 
although the majority of patients (67%) had fewer than 5% blasts. In ALL, 82% of patients 
(n=27) were in CR1 at time of allo-HSCT. Sixty-one percent (n=20) had poor-risk 
cytogenetics, primarily B-ALL associated with t(9;22) in 18 patients. Twenty-one patients 
(8%) received post-transplant therapy for prevention of relapse, 17 with 5-azacitidine for 
high-risk myeloid disease and 4 with a tyrosine kinase inhibitor for Philadelphia 
chromosome–positive ALL.
Survival
At median 5 years' follow-up after the 1-year landmark (range, 0.03–13 years), estimated 5-
year RFS for the entire cohort was 73% (95% confidence interval [CI] 67–78%), and 
estimated 5-year OS was 76% (95% CI 70–81%) (Figure 1). In comparison, in patients 
surviving to 100 days without relapse, 5-year RFS was 56% (95% CI 61–61%) and OS 59% 
(95% CI 54–64%). Those surviving to 180 days without relapse had 5-year RFS of 61% 
(95% CI 56–67%) and OS 64% (95% CI 59–70%). Among all 416 patients transplanted, 5-
year RFS from time of HSCT was 49% (95% CI 44–54%) and OS 52% (95% CI 48–58%) 
(Supplementary Figure).
In AML, estimated 5-year RFS was 77% (95% CI 69–83%), and OS was 80% (95% CI 72–
85%) after the 1-year landmark. For MDS, estimated 5-year RFS and OS were 70% (95% CI 
57–80%) and 71% (95% CI 57–81%), respectively. Estimated 5-year RFS and OS in ALL 
were 62% (95% CI 42–76%) and 72% (95% CI 53–84%), respectively.
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Before the 1-year landmark, 25 patients (9%) had developed grade I, 24 (9%) had developed 
grade II, and 16 (6%) grade III–IV acute GVHD. The remaining 211 patients (76%) had no 
acute GVHD at 1 year. Of the patients with grade III–IV acute GVHD, 3 had received DLI, 
though all had some GVHD preceding DLI. One patient had developed acute GVHD 32 
days after a CD34-selected cell boost. Eighteen patients (7%) had developed chronic GVHD 
before 1 year, with 8 mild (3%), 6 moderate (2%), and 4 (1%) severe.
After the landmark, there were 4 cases (1%) of new acute GVHD, 3 of which followed a 
second allo-HSCT for relapse. None of these patients died of GVHD. Four patients (1%) 
developed new chronic GVHD after 1 year, which was mild in 2 patients and severe in 2 
patients, of whom both died of GVHD. Recipients of mismatched donor grafts overall were 
at higher risk of grade ≥ II acute GVHD or moderate to severe chronic GVHD, which 
developed in 14% of patients receiving grafts from HLA-matched donors and 23% of 
patients with mismatched donors (p=0.05).
Relapse and non-relapse mortality
There were 28 relapses after the landmark with an overall 5-year cumulative incidence of 
relapse of 11% (95% CI,7–15%): 15 in AML (9%, 95% CI 5–14%), 4 in ALL (13%, 95% 
CI 1–26%), and 9 in MDS (13%, 95% CI 4–21%). Median time to relapse in patients with 
disease recurrence after the landmark was 25 months post-transplant (range, 12–119 
months). Among patients with relapse events, 11 were alive at last follow-up, including 6 
who underwent second allo-HSCT. There were 46 deaths without relapse, with a 5-year 
cumulative incidence of NRM of 16% (95% CI 12–21%).
Table 2 details causes of late mortality. GVHD, both acute and chronic, was the most 
common cause of death, accounting for 17 of 63 total deaths (27%), followed closely by 
relapse (n=16, 25%) and infection (n=12, 19%). Of deaths due to viral infection, 2 were 
attributed to EBV, 2 to JC virus, and 1 to CMV. Six patients died of other malignancies, 
including 3 new cancers and 3 recurrences of unrelated cancers that had previously been in 
remission before transplant. In contrast, among patients excluded from the landmark 
analysis due to death or relapse before 1 year, relapse was the most common cause of death 
(n=58 of 136 total deaths, 43%), followed by infection (n=39, 29%; 15 viral, 14 bacterial, 2 
parasitic, 1 fungal, 7 multiple/unknown), organ failure (n=18, 13%), GVHD (n=14, 10%), 
primary graft failure (n=2, 1%), and other or unknown causes (n=5, 4%). In these patients, 
deaths from viral infection were caused by Adenovirus (n = 5) in addition to EBV (n = 5) 
and CMV (n = 4).
Factors associated with late prognosis
In univariate analysis (Table 3), increasing age (HR per 10 years 1.30, 95% CI 1.04–1.62, 
p=0.02), HCT-CI ≥ 3 (HR 2.51, 95% CI 1.28–4.90, p=0.007), and acute GVHD by 1 year 
(HR 2.32, 95% CI 1.39–3.88, p=0.001; figure 3), particularly grade III–IV (HR 5.61, 95% 
CI 2.81–11.22, p<0.0001), significantly correlated with poorer OS; similar associations were 
found for RFS. Chronic GVHD by 1 year did not significantly associate with RFS or OS.
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In multivariate analyses controlling for age, HCT-CI, and grade of acute GVHD by 1 year, 
patients with HCT-CI scores of 3 or higher had significantly worse OS (HR 2.53, 95% CI 
1.26–5.08, p=0.009) and marginally worse RFS (HR 1.78, 95% CI 0.98–3.28, p=0.06), 
compared with those with a score of 0. Patients with an HCT-CI score of 1–2 had a similar 
RFS and OS (Table 3, Figure 2). Increasing grades of acute GVHD were also associated 
with progressively worse RFS and OS by multivariable analysis (Table 3, Figure 4), with 
grade III–IV portending the worst prognosis.
Use of chemotherapy-based conditioning correlated with poorer RFS but not OS on 
univariate analysis. This association was not significant on multivariable analysis (TBI HR 
1.0 [reference]; chemo HR 1.04, 95% CI 0.55–1.97, p=0.90). There was no association 
detected between the method of CD34 selection (ISOLEX versus CliniMACS) and RFS or 
OS.
Table 4 shows results of univariate analysis of the effect of disease-related factors on 
survival. Intermediate- or high-risk AML correlated with marginally worse RFS on 
univariate analysis (p=0.08), with HR of 5.16 for intermediate risk (95% CI 0.69–38.37, 
p=0.11) and 7.98 for poor risk (95% CI 1.05–60.39, p=0.04). The difference in OS was not 
significant (p=0.25). Among patients with ALL, entering transplant in CR2 or with 
refractory disease significantly correlated with worse RFS compared with CR1, with HR 
4.56 (95% CI 1.41–14.79, p=0.01), and marginally correlated with poorer OS (HR 3.51, 
95% CI 0.94–12.12, p=0.06). In MDS, none of the evaluated disease features, including pre-
HSCT disease status, cytogenetic risk, or IPSS-R at diagnosis or before HSCT, corresponded 
with a significant difference in RFS or OS.
Discussion
This study demonstrates that patients who receive CD34-selected allo-HSCT for AML, 
ALL, or MDS and survive without relapse past 1 year have an excellent prognosis. The high 
probability of long-term RFS and OS and low incidence of late relapse seen in our study 
meet or exceed those same outcomes in earlier landmark analyses of survivors of 
myeloablative allo-HSCT that did not distinguish between TCD and unmodified grafts.11, 12 
Most recently, Lee et al. reported adult patients with acute leukemia who underwent allo-
HSCT between 1990 and 2005, and were alive and relapse-free at 1 year, noting a 5-year 
RFS of 78% in AML and 71% in ALL,12 similar to that seen in our cohort. Of note, the 
median ages of patients included in that prior analysis were 37 years in AML and 29 years in 
ALL, with a minority of patients over 50 years, in contrast to a median age of 54 years in 
this study population. Prior comparisons of CD34-selected allo-HSCT with unmodified 
grafts have likewise shown comparable survival between the two approaches despite older 
patient age in the CD34-selected cohorts.8, 9 These results raise the possibility that CD34-
selected allo-HSCTs might allow older patients to receive the antileukemic benefit of 
myeloablative conditioning without excessive risk of late mortality.
Late mortality persists due to both relapse and NRM, however; and we have identified risk 
factors that represent key areas of unmet need. Among patient-specific factors with 
prognostic significance, an HCT-CI score of 3 or greater correlated with poorer survival, a 
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finding concordant with our analyses elsewhere of CD34-selected allo-HSCT for AML and 
MDS.19 Also consistent with our prior findings, patients in this cohort with an HCT-CI score 
of 1–2 had similar long-term survivals to those with a score of 0. This indicates that the use 
of CD34 selection attenuates late NRM in such patients with more modest comorbidity 
burdens compared with unmodified myeloablative allo-HSCT, and that such patients may be 
optimal candidates for consideration of CD34 selected allo-HSCT. Further research should 
enhance our understanding of the influence exerted by comorbidities in the CD34 selection 
setting, which will in turn optimize patient selection. Patients with more substantial 
comorbidities remain in need of additional strategies to attenuate NRM.
Although CD34 selection resulted in a low incidence of acute and chronic GVHD, those few 
patients who had developed acute GVHD at any time before 1 year, particularly grade III–
IV, had a poor prognosis. GVHD, though uncommon after the 1-year landmark, was the 
most common cause of death. Even with CD34 selection, the use of mismatched donor 
allografts and DLI in particular expose patients to heightened risk of GVHD. We did not 
detect a difference in survival for patients with chronic GVHD, which has been identified as 
a risk factor for late mortality in the previous CIBMTR landmark analyses.11, 12 With very 
few patients with chronic GVHD, however, our sample was likely too small to detect a 
difference, and despite an extremely small number of patients with moderate to severe 
chronic GVHD before or after the 1-year landmark, a disproportionate number died of 
chronic GVHD or an acute/chronic GVHD overlap syndrome. Our data thus highlight the 
need for further strategies to recognize patients at heightened risk of both acute and chronic 
GVHD despite CD34 selection, to diagnose GVHD at an earlier stage, and to manage it 
effectively.
Infection, especially viral infection, was another major cause of late mortality, underscoring 
the role of post-transplant lymphopenia, which is more pronounced with CD34 
selection.20, 21 Novel strategies to enhance immune reconstitution after CD34-selected allo-
HSCT are indicated.22 Of particular interest, as the use of CD34 selection obviates the need 
for pharmacologic GVHD prophylaxis, it represents a suitable platform for the study and 
implementation of cell- and immune-based approaches to enhance post-transplant immunity 
without increasing risk of GVHD, including the use of cytotoxic lymphocytes directed 
against viral or leukemic antigens, checkpoint inhibitors, and cytokine-based therapies.
The modest contribution of many disease-related factors including cytogenetic risk and 
remission status on long-term prognosis indicates that the effect of such variables recedes 
over time in patients who are able to survive without relapse past the initial post-HSCT 
period. Although our analysis was limited by incomplete data regarding pre-HSCT minimal 
residual disease (MRD), which portends a high risk of post-HSCT relapse in both AML and 
ALL,23-25 this effect largely influences relapse earlier post-transplant. The specific impact 
on late relapse remains unknown. We also lacked complete data on molecular markers in 
AML for the majority of patients, including the presence of FLT3, NPM1, CEBPA, or c-kit 
mutations, due to the retrospective design of this analysis. Such information would have 
facilitated more complete risk stratification by contemporary methods and will be 
incorporated in future analyses.
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While encouraging, these retrospective findings require prospective confirmation. To this 
end, TCD is currently under investigation in a national phase III randomized trial, BMT 
CTN 1301 (NCT02345850), comparing CD34 selection with post-transplant 
cyclophosphamide versus standard GVHD prophylaxis with tacrolimus and methotrexate.
In summary, for the patient who undergoes CD34-selected PBSCT and is alive without 
disease at the 1-year landmark, long-term survival is excellent in the absence of substantial 
comorbidities and GVHD. Efforts to improve identification of patients at risk for late events, 
and strategies to treat such patients while taking advantage of the properties of the CD34 
selection platform, constitute vital areas of future research to improve even further on these 
outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Relapse-free and overall survival for all patients
Kaplan-Meier estimates of (A) relapse-free survival and (B) overall survival for the entire 
cohort, measured in years after the 1-year landmark. Estimated 5-year RFS was 73% (95% 
CI 67–78%), and estimated 5-year OS was 76% (95% CI 70–81%).
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Figure 2. Survival according to HCT-CI
Kaplan-Meier estimates of (A) relapse-free survival and (B) overall survival according to 
HCT-CI score, measured in years after the 1-year landmark. On multivariate analysis, HCT-
CI score of 3 or greater was associated with marginally poorer RFS (HR 1.78, 95% CI 0.97–
3.20, p=0.06) and significantly poorer OS (HR 2.53, 95% CI 1.26–5.08, p=0.009).
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Figure 3. Survival according to presence of acute GVHD before 1 year
Kaplan-Meier estimates of (A) relapse-free survival and (B) overall survival according to the 
presence of acute GVHD of any grade, measured in years after the 1-year landmark. In 
univariate analysis, the presence of acute GVHD before 1 year was significantly associated 
with poorer RFS (HR 2.17, 95% CI 1.34–3.50, p=0.002) and poorer OS (HR 2.32, 95% CI 
1.39–3.88, p=0.001).
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Figure 4. Survival according to grade of acute GVHD prior to 1 year
Kaplan-Meier estimates of (A) relapse-free survival and (B) overall survival according grade 
of acute GVHD, measured in years after the 1-year landmark. Higher grades of acute GVHD 
correlated with progressively worse survival, with grade III–IV acute GVHD associated with 
the poorest RFS and OS. On multivariate analysis, grade II and grade III–IV aGVHD were 
associated with increasingly worse RFS (grade II: HR 2.07, 95% CI 1.01–4.27, p=0.05; 
grade III–IV: HR 6.14, 95% CI 3.12–12.07; p<0.001) and OS (grade II: HR 2.90, 95% CI 
1.39–6.04, p=0.005; grade III–IV: HR 6.14, 95% CI 3.05–12.36, p<0.001).
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Table 1
Patient and transplant characteristics
Characteristic Value Value
All patients transplanted Patients in landmark cohort
n=416 n=276
Median age (range), years 54 (18–73) 54 (18–72)
Male, n (%) 230 (55) 150 (54)
Disease, n (%)
 AML 252 (61) 164 (59)
 ALL 57 (14) 33 (12)
 MDS 107 (26) 79 (29)
KPS, n (%)
 90–100 222 (53) 160 (58)
 80 147 (35) 94 (34)
 <80 27 (6) 14 (5)
 Data not available 20 (5) 8 (3)
HCT-CI, n (%)
 0 88 (21) 72 (26)
 1–2 130 (31) 90 (33)
 ≥ 3 (range, 3–10) 198 (48) 114 (41)
Conditioning regimen, n (%)
 TBI/thiotepa/fludarabine 85 (20) 53 (19)
 TBI/thiotepa/cyclophosphamide 79 (19) 53(19)
 Busulfan/melphalan/fludarabine 241 (58) 163 (59)
 Clofarabine/melphalan/thiotepa 11 (3) 8 (3)
Donor type, n (%)
 8/8-matched related 155 (37) 108 (39)
 8/8-matched unrelated 159 (38) 101 (37)
 Mismatched related 11 (3) 8 (3)
  7/8-matched, n  9  6
  6/8-matched, n  2  2
 Mismatched unrelated 91 (22) 59 (21)
  7/8-matched, n  85  55
  6/8-matched, n  6  4
CD34 selection method, n (%)
 ISOLEX 300i and sRBC 241 (58) 158 (57)
 CliniMACS 175 (42) 118 (43)
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Characteristic Value Value
All patients transplanted Patients in landmark cohort
n=416 n=276
Antithymocyte globulin (ATG), n (%)
 Any ATG 376 (90) 248 (90)
 Rabbit ATG (2.5-10 mg/kg) 301 (72) 202 (73)
 Equine ATG (30–45 mg/kg) 73 (18) 46 (17)
 Rabbit and equine ATG 2 (<1) 0 (0)
AML n=251 n=164
Disease status at HSCT, n (%)
 CR1 171 (68) 116 (71)
 CR2 or greater 68 (27) 40 (24)
 PR 9 (4) 6 (4)
 Refractory 3 (1) 2 (1)
Risk group, n (%)
 Favorable 20 (8) 18 (11)
 Intermediate 139 (55) 95 (58)
 Poor 91 (36) 51 (31)
 Unknown 1 (<1) 0
Therapy-related AML, n (%) 34 (14) 22 (13)
FLT3-ITD or -TKD, n (%)
 Positive 26 (10) 19 (12)
 Negative 67 (27) 43 (26)
 Data not available 157 (63) 102 (62)
Isolated NPM1 mutation, n (%)
 Yes 5 (2) 4 (2)
 No 63 (25) 42 (26)
 Data not available 183 (73) 118 (72)
ALL n=57 n=33
Disease status at HSCT, n (%)
 CR1 43 (75) 27 (82)
 CR2 or greater 13 (23) 5 (15)
 Refractory 1 (2) 1 (3)
Cytogenetic risk, n (%)
 Standard/good 23 (40) 13 (39)
 Poor 34 (60) 20 (61)
Phenotype, n (%)
 B-cell 46 (81) 27 (82)
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Characteristic Value Value
All patients transplanted Patients in landmark cohort
n=416 n=276
  BCR-ABL1+ 28 (49) 18 (55)
 T-cell 9 (16) 5 (15)
 B/T-cell or NK 2 (4) 1 (3)
MDS n=108 n=79
Disease status at HSCT, n (%)
 CR 22 (20) 14 (18)
 Non-CR 86 (80) 65 (82)
  <5% blasts  69 (64)  53 (67)
  5–10% blasts  14 (13)  9 (11)
  Unknown  3 (3)  3 (4)
Therapy received pre-HSCT, n (%) 91 (84) 67 (85)
IPSS-R at diagnosis, n (%)
 Very low 5 (5) 3 (4)
 Low 21 (19) 15 (19)
 Intermediate 31 (29) 28 (35)
 High 19 (18) 15 (19)
 Very high 21 (19) 12 (15)
 Data not available 11 (10) 6 (8)
IPSS-R at HSCT, n (%)
 Very low 5 (5) 4 (5)
 Low 36 (33) 30 (38)
 Intermediate 38 (35) 25 (32)
 High 17 (16) 11 (14)
 Very high 9 (8) 6 (8)
 Data not available 3 (3) 3 (4)
 Therapy-related MDS, n (%) 24 (22) 13 (16)
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Table 2
Causes of death among patients who died after the 1-year landmark
Total deaths, n 63
GVHD, n (%) 17 (27)
 Acute, n  9
 Chronic, n  6
 Acute/chronic, n  2
Relapse, n (%) 16 (25)
 Relapse within 2 years of HSCT, n  9
Infection, n (%) 12 (19)
 Viral, n  5
 Multiple or unknown, n  7
Organ failure, n (%) 9 (14)
 Multiple, n  2
 Pulmonary, n  3
 Cardiac, n  1
 Liver, n  2
 Renal, n  1
Other malignancy, n (%) 6 (10)
 Secondary malignancy, n  3
 Recurrence of other primary malignancy, n  3
Other/unknown, n (%) 3 (5)
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